Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-04-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于全资子公司五项新冠检测产品完成CE认证的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the completion of CE certification for five new COVID-19 testing products by its wholly owned subsidiary. It details product information, market context, and potential impact on the company. The document is relatively short (3352 characters) and does not contain financial statements, management discussion, or detailed financial data. It is not a report like an Annual Report, Interim Report, or Earnings Release. Instead, it is a regulatory announcement about product certification and market impact. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-04-29 Chinese
关于以集中竞价方式回购部分社会公众股份方案的补充公告
Transaction in Own Shares Classification · 95% confidence The document is a supplemental announcement regarding a share repurchase plan by Shenzhen BGI Genomics Co., Ltd. It discusses details about insider trading checks, shareholding changes, and future share reduction plans by major shareholders and insiders. The text references a previous announcement about the share repurchase plan and clarifies that the supplement does not change the substance of the original plan. The document is relatively short (2944 characters) and is an announcement about the share repurchase plan, not the plan or report itself. This fits the category of a Transaction in Own Shares (POS) filing, which covers announcements related to share buybacks or repurchases.
2020-04-28 Chinese
关于对深圳证券交易所关注函的回复公告
Regulatory Filings Classification · 95% confidence The document is a detailed reply announcement from Shenzhen BGI Genomics Co., Ltd. to a regulatory inquiry from the Shenzhen Stock Exchange. It includes extensive disclosures about the company's COVID-19 test kit certifications, market risks, sales, production capacity, stock price movements, insider trading checks, share repurchase plans, and bond issuance results. The document is regulatory in nature, addressing compliance and disclosure requirements, and includes multiple announcements about share repurchases and bond issuance results. It is not a full annual or quarterly report, earnings release, or management discussion. It is also not a simple announcement of a report publication but a substantive regulatory disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories. The document length (over 12,000 characters) and detailed content support this classification with high confidence.
2020-04-28 Chinese
关于以集中竞价方式回购部分社会公众股份方案的公告（更新后）
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement from Shenzhen BGI Genomics Co., Ltd. regarding a share repurchase plan using the company's own funds through centralized bidding. It includes specifics about the purpose, amount, price limits, implementation period, risks, and approvals related to the share buyback. The document also discusses the impact on the company's financials and shareholding structure, and includes independent directors' opinions supporting the plan. The content is focused on the company's plan to repurchase its own shares and the related procedural and regulatory disclosures. This matches the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back or selling its own shares (share repurchase/issuance). The document is not a full financial report, earnings release, or other types of filings, but a detailed announcement of a share repurchase plan.
2020-04-28 Chinese
2020年面向合格投资者公开发行公司债券（第一期）发行结果公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the issuance results of a corporate bond by Shenzhen BGI Genomics Co., Ltd. It details the bond issuance scale, pricing, types, guarantees, terms, and final issuance results. The content focuses on financing activities and capital raising. The document length is short (788 characters) and it is a formal announcement of the bond issuance results, not a full financial report or detailed financial statements. Therefore, it fits the category of Capital/Financing Update (CAP).
2020-04-27 Chinese
关于全资子公司签署重大经营合同的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Shenzhen BGI Genomics Co., Ltd. regarding the signing of a major business contract by its wholly-owned subsidiary with a Saudi Arabian company. It details the contract amount, terms, risks, and expected impact on the company's business. The document is relatively short (3158 characters) and focuses on disclosing a significant contract event rather than providing financial statements or detailed financial performance data. There is no indication that this is a full financial report, audit report, or earnings release. It is a regulatory announcement about a material contract signing, which fits best under the category of Regulatory Filings (RNS) as it does not fit other more specific categories like Capital/Financing Update or M&A Activity. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-04-27 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.